Selehold 45 mg spot-on solution for cats 2.6–7.5 kg

Authorised

This information is not available for this product.

Product identification

Medicine name:
Selehold 45 mg soluzione spot-on per gatti 2,6 – 7,5 kg
Selehold 45 mg spot-on solution for cats 2.6–7.5 kg

Active substance:
This information is not available for this product.

Target species:
Cat

Route of administration:
Spot-on use

Product details

Active substance and strength:
This information is not available for this product.

Pharmaceutical form:
Spot-on solution

Withdrawal period by route of administration:

Spot-on use:

- **Cat**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AA05

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Italy

Package description:
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 0.75 ml of solution.Cardboard box containing 1 pipette.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 0.75 ml of solution.Cardboard box containing 3 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 0.75 ml of solution.Cardboard box containing 6 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 0.75 ml of solution.Cardboard box containing 15 pipettes.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
12/11/2020

Manufacturing sites for batch release:
Krka d.d. Novo Mesto
Tad Pharma GmbH

Responsible authority:
Ministry Of Health

Authorisation number:
105194

Date of authorisation status change:
12/11/2020

Reference member state:
Ireland

Procedure number:
IE/V/0394/002

Concerned member states:
Belgium Bulgaria Croatia Czechia Estonia France Germany Greece Hungary Italy Latvia Lithuania Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
